S&P 500

5.277,51

0,80%

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Eterna Therapeutics Inc (ERNA)
Eterna Therapeutics Inc (ERNA) Notícias

ERNA

Eterna Therapeutics (ERNA)

Eterna Therapeutics Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:ERNA

1 2 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
14/05/2024	18:14	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ERNA	Eterna Therapeutics Inc
10/05/2024	09:00	GlobeNewswire Inc.	Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs i	NASDAQ:ERNA	Eterna Therapeutics Inc
08/05/2024	10:31	GlobeNewswire Inc.	Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board	NASDAQ:ERNA	Eterna Therapeutics Inc
07/05/2024	09:00	GlobeNewswire Inc.	Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus	NASDAQ:ERNA	Eterna Therapeutics Inc
20/02/2024	10:30	GlobeNewswire Inc.	Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors	NASDAQ:ERNA	Eterna Therapeutics Inc
16/02/2024	19:30	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:ERNA	Eterna Therapeutics Inc
16/02/2024	09:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ERNA	Eterna Therapeutics Inc
31/01/2024	09:05	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ERNA	Eterna Therapeutics Inc
24/01/2024	18:15	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:ERNA	Eterna Therapeutics Inc
23/01/2024	02:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ERNA	Eterna Therapeutics Inc
16/01/2024	18:16	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ERNA	Eterna Therapeutics Inc
12/01/2024	18:49	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ERNA	Eterna Therapeutics Inc
03/01/2024	19:02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ERNA	Eterna Therapeutics Inc
03/01/2024	18:15	GlobeNewswire Inc.	Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)	NASDAQ:ERNA	Eterna Therapeutics Inc
22/12/2023	14:05	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:ERNA	Eterna Therapeutics Inc
20/12/2023	18:15	GlobeNewswire Inc.	Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer	NASDAQ:ERNA	Eterna Therapeutics Inc
20/12/2023	17:24	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:ERNA	Eterna Therapeutics Inc
14/12/2023	20:56	GlobeNewswire Inc.	Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing	NASDAQ:ERNA	Eterna Therapeutics Inc
01/11/2023	09:30	GlobeNewswire Inc.	Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors	NASDAQ:ERNA	Eterna Therapeutics Inc
26/09/2023	17:30	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:ERNA	Eterna Therapeutics Inc
06/09/2023	09:00	GlobeNewswire Inc.	Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics	NASDAQ:ERNA	Eterna Therapeutics Inc
05/09/2023	09:30	GlobeNewswire Inc.	Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors	NASDAQ:ERNA	Eterna Therapeutics Inc
26/07/2023	12:50	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:ERNA	Eterna Therapeutics Inc
18/07/2023	09:00	GlobeNewswire Inc.	Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt Financing	NASDAQ:ERNA	Eterna Therapeutics Inc
11/07/2023	09:30	GlobeNewswire Inc.	Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors	NASDAQ:ERNA	Eterna Therapeutics Inc
24/05/2023	09:30	GlobeNewswire Inc.	Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel	NASDAQ:ERNA	Eterna Therapeutics Inc
17/05/2023	09:30	GlobeNewswire Inc.	Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting	NASDAQ:ERNA	Eterna Therapeutics Inc
11/05/2023	17:35	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:ERNA	Eterna Therapeutics Inc
10/05/2023	07:02	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:ERNA	Eterna Therapeutics Inc
05/05/2023	08:02	Edgar (US Regulatory)	Annual Report to Security Holders (ars)	NASDAQ:ERNA	Eterna Therapeutics Inc